Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong demand for its glucose-monitoring products and other medical devices.

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read an analysis of ABT stock now.

The CEO at the Illinois-based company with operations in Minnesota expects earning to return to a pre-pandemic profit model as Covid-19 test sales have less of an effect on sales.

Key Takeaways Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices.Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and nutrition divisions.

Abbott ($ABT) reported better-than-expected third-quarter results on Wednesday. The medical devices and healthcare company’s sales increased by

Abbott has raised the midpoint of its full-year income guidance as the group was bolstered by solid sales of medical devices and targeted new product approvals. The Illinois-based company said it now expects to deliver annual

Abbott Laboratories (NYSE:ABT) increased its full-year earnings guidance on Tuesday after its financials for Q3 2024 exceeded Wall Street's forecasts, thanks mainly to the strength in its Pharma and MedTech segments.